Pasithea Therapeutics公布一期晚期癌症研究积极中期数据

投资观察
Jul 06

Pasithea Therapeutics Corp.宣布,其针对晚期癌症的一期研究获得了积极的中期数据,结果显示在经MEK/BRAF预处理的患者中,其药物展现出长期安全性、耐受性以及持久的临床活性。公司同时宣布了研究方案的扩展计划。

数据显示,候选药物PAS-4展现出良好的安全性特征,仅观察到1级或2级不良事件。此外,研究方案已获修订,将PAS-4的剂量递增范围扩展至最高52毫克。

为进一步评估药物特性,公司已启动一项关于PAS-4药代动力学的初步食物效应研究。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10